Galen and POA Pharma unveil Galsana, a new global brand for rare metabolic diseases
Friday, August 21, 2026
At the SSIEM Annual Symposium in Helsinki, Galen Ltd and POA Pharma announced the launch of Galsana, a new global brand for their metabolic product portfolio, bringing together established products, expertise and support services under a single identity.
Galsana represents the next stage in the evolution of the company's medical nutrition business, creating a clearer and more consistent platform for engagement with patients, healthcare professionals and partners across international markets.
Building on Galen's heritage as a Northern Ireland head-quartered pharmaceutical company and strengthened by the acquisition of Sweden-based POA Pharma in 2020, Galsana combines complementary expertise to support people living with rare metabolic diseases while advancing innovation and fostering collaboration across the global community.
Dr Dennise Broderick, Managing Director and President at Galen Ltd, said:
“Since entering this specialist area, our focus has been on understanding the day-to-day needs of people living with rare metabolic conditions and developing products and services that offer greater choice and support.
“Our commitment to this therapy area reflects our long-term ambition to advance innovation and deliver better everyday outcomes for patients and their families. Galsana brings that work together under a single global identity that better reflects who we are today and the ambition we have for the future.
“Importantly, while the name is changing, the products, quality standards and support people rely on remain the same. What Galsana provides is a stronger foundation to expand choice, strengthen support and continue innovating in the years ahead.
“Guided by Galsana’s Patient First Innovation philosophy, Galen and POA Pharma will continue to invest in product development, educational resources and practical initiatives designed to improve quality of life, support day-to-day disease management and respond to the evolving needs of the metabolic disease community.”
Dr Sarah Dolan, Associate Director of Medical Nutrition at Galen Ltd, added:
“Galsana marks an exciting new chapter for our business. By bringing our portfolio together under one identity, we can create a more consistent experience for the metabolic disease community - healthcare professionals, patients and partners alike – while strengthening our reach across international markets.
“Products such as our PKU EASY Microtabs and PKU EASY Microtabs Plus demonstrate what Patient First Innovation means in practice - developing practical, game-changing options across rare metabolic conditions including PKU, TYR, HCU, UCD and MSUD.
“As Galsana grows, we want to build on that approach, bringing forward similar innovations that are grounded in trust, guided by patients and shaped around the real needs of those managing rare metabolic conditions.”
To learn more about Galsana, its product portfolio and commercial partnership opportunities, visit www.galsana.com
Photos: Galsana growing for the future 1&3
Caption: Growing for the future. Pictured at the launch of Galen’s new global brand, Galsana, are Dr Dennise Broderick, Managing Director and President; Simon Lawrence, Vice President of Marketing and Medical Nutrition and Dr Sarah Dolan, Associate Director of Medical Nutrition.
About Galsana
As a subsidiary of Galen Limited, Galsana offers a variety of innovative medical foods for use in the dietary management of metabolic disorders. Formulas are available for disorders such as Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), and Tyrosinemia (TYR) as well as Urea Cycle Disorders (UCD).
Galsana is committed to bringing innovation, quality, and customer focus to people with metabolic disorders.
For further information please visit: www.galsana.com
About Galen
Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland) and with product presence in 25 locations covering every continent across the globe.
With over 55 years’ experience, Galen has 75+ products across a diverse range of therapy areas.
Galen has ambitious expansion plans across new territories and therapeutic areas through the acquisition of new companies and product portfolios as well as product partnerships. Galen aims to provide extraordinary service to healthcare professionals, partners, and patients to create real, long-term value and benefit the health of future generations.
For further information please visit: www.galen-pharma.com
About POA Pharma
Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.
For further information please visit: https://poapharma.com
About Almac Group
Galen is a member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally. The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health. The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 7,900 highly skilled personnel across 18 facilities including Europe, the US and Asia.
For further information please visit: www.almacgroup.com
